A Prospective, Randomized, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (non-cardiac) Surgery in Paediatric Patients
Phase of Trial: Phase IV
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Fibrin (Primary) ; Fibrin (Primary) ; Oxidised cellulose
- Indications Surgical blood loss
- Focus Therapeutic Use
- Sponsors Ethicon
- 17 Sep 2019 Planned End Date changed from 1 Jan 2020 to 31 Dec 2020.
- 17 Sep 2019 Planned primary completion date changed from 1 Dec 2019 to 30 Nov 2020.
- 12 Dec 2017 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.